SF-9-2

• Description:

  SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM) . SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Bcl-2 Family; Cadherin; Caspase; ERK; GSK-3; IFNAR; JNK; p38 MAPK; PD-1/PD-L1

• Related Pathways:

  Apoptosis; Cytoskeleton; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  N#CC1=CC(COC2=C(C=CC(OCC3=C(C(C4=CC=CC=C4F)=CC=C3)CF)=C2)CNCCO)=CN=C1

• Molecular Formula:

  C30H27F2N3O3

• Molecular Weight:

  515.55

• References & Citations:

  [1]Jianwei Wang et al. Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways. ACS Pharmacol. Transl. Sci.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Caspase 3; GSK-3β

• CAS Number:

  [3053768-78-5]